Literature DB >> 30891145

Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors.

Chunjian Liu1, James Lin1, Ryan Moslin1, John S Tokarski1, Jodi Muckelbauer1, ChiehYing Chang1, Jeffrey Tredup1, Dianlin Xie1, Hyunsoo Park1, Peng Li1, Dauh-Rurng Wu1, Joann Strnad1, Adriana Zupa-Fernandez1, Lihong Cheng1, Charu Chaudhry1, Jing Chen1, Cliff Chen1, Huadong Sun1, Paul Elzinga1, Celia D'arienzo1, Kathleen Gillooly1, Tracy L Taylor1, Kim W McIntyre1, Luisa Salter-Cid1, Louis J Lombardo1, Percy H Carter1, Nelly Aranibar1, James R Burke1, David S Weinstein1.   

Abstract

In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stability. The N1-substituent on 2-oxo-1,2-dihydropyridine ring can be a variety of alkyl, aryl, and heteroaryl groups, but among them, 2-pyridyl provided much enhanced Caco-2 permeability, attributed to its ability to form intramolecular hydrogen bonds. Further structure-activity relationship studies at the C3 position led to the identification of highly potent and selective Tyk2 JH2 inhibitor 6, which proved to be highly effective in inhibiting IFNγ production in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model.

Entities:  

Year:  2019        PMID: 30891145      PMCID: PMC6421589          DOI: 10.1021/acsmedchemlett.9b00035

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  27 in total

1.  A heritable defect in IL-12 signaling in B10.Q/J mice. I. In vitro analysis.

Authors:  R Ortmann; R Smeltz; G Yap; A Sher; E M Shevach
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

Review 2.  Regulation of JAK-STAT signalling in the immune system.

Authors:  Ke Shuai; Bin Liu
Journal:  Nat Rev Immunol       Date:  2003-11       Impact factor: 53.106

Review 3.  Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.

Authors:  Alaa-Eldin F Nassar; Amin M Kamel; Caroline Clarimont
Journal:  Drug Discov Today       Date:  2004-12-01       Impact factor: 7.851

4.  Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies.

Authors:  A A Bengtsson; G Sturfelt; L Truedsson; J Blomberg; G Alm; H Vallin; L Rönnblom
Journal:  Lupus       Date:  2000       Impact factor: 2.911

5.  Type I interferon correlates with serological and clinical manifestations of SLE.

Authors:  M C Dall'era; P M Cardarelli; B T Preston; A Witte; J C Davis
Journal:  Ann Rheum Dis       Date:  2005-04-20       Impact factor: 19.103

6.  In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.

Authors:  Gamze Piskin; Regien M R Sylva-Steenland; Jan D Bos; Marcel B M Teunissen
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

7.  Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers -- IL-12, IL-18 and IL-23.

Authors:  G Piskin; U Tursen; R M R Sylva-Steenland; J D Bos; M B M Teunissen
Journal:  Exp Dermatol       Date:  2004-12       Impact factor: 3.960

8.  Interleukin 12 production by monocytes from patients with psoriasis and its inhibition by ciclosporin A.

Authors:  Y Tada; A Asahina; T Takekoshi; E Kishimoto; H Mitsui; H Saeki; M Komine; K Tamaki
Journal:  Br J Dermatol       Date:  2006-06       Impact factor: 9.302

9.  JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.

Authors:  Judith Staerk; Anders Kallin; Jean-Baptiste Demoulin; William Vainchenker; Stefan N Constantinescu
Journal:  J Biol Chem       Date:  2005-10-19       Impact factor: 5.157

10.  Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.

Authors:  Edmund Lee; William L Trepicchio; Judith L Oestreicher; Debra Pittman; Frank Wang; Francesca Chamian; Madhav Dhodapkar; James G Krueger
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

View more
  4 in total

1.  Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.

Authors:  Yu Zhou; Xin Li; Ru Shen; Xiangzhu Wang; Fan Zhang; Suxing Liu; Di Li; Jian Liu; Puhui Li; Yinfa Yan; Ping Dong; Zhigao Zhang; Heping Wu; Linghang Zhuang; Rasheduzzaman Chowdhury; Matthew Miller; Mena Issa; Yuchang Mao; Hongli Chen; Jun Feng; Jing Li; Chang Bai; Feng He; Weikang Tao
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

Review 2.  TYK2: An Upstream Kinase of STATs in Cancer.

Authors:  Katharina Wöss; Natalija Simonović; Birgit Strobl; Sabine Macho-Maschler; Mathias Müller
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

3.  Inducible knockout of Clec16a in mice results in sensory neurodegeneration.

Authors:  Steven S Scherer; Hakon Hakonarson; Heather S Hain; Rahul Pandey; Marina Bakay; Bryan P Strenkowski; Danielle Harrington; Micah Romer; William W Motley; Jian Li; Eunjoo Lancaster; Lindsay Roth; Judith B Grinspan
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

4.  Synthesis of 1,4,5,6-tetrahydropyridazines and pyridazines via transition-metal-free (4 + 2) cycloaddition of alkoxyallenes with 1,2-diaza-1,3-dienes.

Authors:  Qi Wu; Pan-Lin Shao; Yun He
Journal:  RSC Adv       Date:  2019-07-10       Impact factor: 4.036

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.